GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Sustainability, MDPI AG, Vol. 15, No. 13 ( 2023-06-29), p. 10330-
    Abstract: The worldwide population is undergoing a fundamental change in its age structure, which challenges the health- and social-services system. The need to migrate towards a more person-centered and coordinated model of care that supports the optimization of abilities and capacities for older people has to be matched. In this sense, eHealth technologies can play a fundamental role. In this paper, through a questionnaire-based data collection using 30 primary (older people) and 32 secondary (informal caregivers) end-users, we share our vision on how to sustainably develop a product by optimizing the user experience and ensuring adoption. We hypothesized that a technology-based intervention can promote healthy ageing through informed and active user involvement at all stages of the care process. Both older adults and caregivers consider the use of a smartphone and smartwatch to be very important; in addition, the use of digital devices for healthcare can be helpful. Seniors care about self-monitoring health parameters through the use of wearable devices, regardless of their health status, and would like to be included in the process of making good health decisions, because they need to feel in control of their healthcare process. Digital solutions in health and care can support the well-being of older adults in many areas of their daily lives, both at home and in their communities, but only if such innovation is designed around the natural voice of the intended target.
    Type of Medium: Online Resource
    ISSN: 2071-1050
    Language: English
    Publisher: MDPI AG
    Publication Date: 2023
    detail.hit.zdb_id: 2518383-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Medicina, MDPI AG, Vol. 58, No. 4 ( 2022-04-03), p. 511-
    Abstract: Dabrafenib and trametinib are two available molecules that have been approved for the treatment of metastatic melanoma with BRAF-V600E or V600K mutations. Their combined therapy has led to long-lasting survival benefits and substantially improved outcomes. Until now, only a few cases of severe hypersensitivity reactions to dabrafenib and vemurafenib have been reported, and even fewer desensitization protocols to these molecules have been documented. We report the case of a 71-year-old female patient with metastatic melanoma harboring a BRAF-V600E mutation undergoing targeted therapy with dabrafenib and trametinib. Two weeks after the initiation of the combined treatment, she developed a hypersensitivity reaction. The cause–effect relationship between dabrafenib and the hypersensitivity reaction was demonstrated twice, when symptoms recurred upon dabrafenib reintroduction. We started a rapid 3-day dabrafenib desensitization protocol, which was well tolerated. When the patient discontinued the drug administration, we decided on a longer protocol that included more steps and more days in order to prevent the occurrence of other hypersensitivity reactions. Our patient tolerated both rapid and slow-going schedules, the first one reaching the final dose within 3 days and the second one reaching the total daily dose within 14 days. Depending on the patient’s needs, the severity of the hypersensitivity reaction and the hospital’s availability, the doctor may choose either the rapid or slow-going desensitization protocol.
    Type of Medium: Online Resource
    ISSN: 1648-9144
    Language: English
    Publisher: MDPI AG
    Publication Date: 2022
    detail.hit.zdb_id: 2088820-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...